|
KMID : 0811720160200040333
|
|
Korean Journal of Physiology & Pharmacology
2016 Volume.20 No. 4 p.333 ~ p.340
|
|
|
Effect of edaravone in diabetes mellitus-induced nephropathy in rats
|
|
Rajavel Varatharajan
Li Xin Lim
Kelly Tan
Chai Sze Tay
Yi Leng Teoh
Shaikh Sohrab Akhtar
Mani Rupeshkumar
Pitchai Balakumar
Nor Azizan Abdullah
Ivy Chung
Urmila Banik
Sokkalingam A. Dhanaraj
|
|
|
Abstract
|
|
|
|
Edaravone, a synthetic-free radical scavenger, has been reported to reduce ischemia-reperfusion-induced renal injury by improving tubular cell function, and lowering serum creatinine and renal vascular resistance. The present study investigated the effect of edaravone in diabetes mellitus-induced nephropathy in rats. A single administration of streptozotocin (STZ, 55 mg/kg, i.p.) was employed to induce diabetes mellitus in rats. The STZ-administered diabetic rats were allowed for 10 weeks to develop nephropathy. Mean body weight, lipid alteration, renal functional and histopathology were analysed. Diabetic rats developed nephropathy as evidenced by a significant increase in serum creatinine and urea, and marked renal histopathological abnormalities like glomerulosclerosis and tubular cell degeneration. The kidney weight to body weight ratio was increased. Moreover, diabetic rats showed lipid alteration as evidenced by a signi? cant increase in serum triglycerides and decrease in serum high-density lipoproteins. Edaravone (10 mg/kg, i.p., last 4-weeks) treatment markedly prevented the development of nephropathy in diabetic rats by reducing serum creatinine and urea and preventing renal structural abnormalities. In addition, its treatment, without significantly altering the elevated glucose level in diabetic rats, prevented diabetes mellitus-induced lipid alteration by reducing serum triglycerides and increasing serum high-density lipoproteins. Interestingly, the renoprotective e? ect of edaravone was comparable to that of lisinopril (5 mg/kg, p.o, 4 weeks, standard drug). Edaravone prevented renal structural and functional abnormalities and lipid alteration associated with experimental diabetes mellitus. Edaravone has a potential to prevent nephropathy without showing an anti-diabetic action, implicating its direct renoprotection in diabetic rats.
|
|
|
KEYWORD
|
|
|
Diabetic nephropathy, Edaravone, Lipid alteration, Renoprotection
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|
|